Skip to content

US · MRNA · BIOTECHNOLOGY

Moderna, Inc. (MRNA) intrinsic value and stock valuation

$195.00as of 2026-11-21 · Mkt cap 23.48B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Moderna, Inc. DCF and intrinsic value

InvestorsCraft values MRNA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from MRNA’s statements →

Moderna, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 modernatx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$1.94B+19.3% 5y CAGRd
20162025
Net income
-$-2.82B
20162025
Free cash flow
-$-2.07B
20162025
Total equity
$8.65B+27.6% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$1.94B$3.2B$6.85B$18.9B$17.7B
Operating income-$-3.07B-$-3.95B-$-4.24B$9.42B$13.3B
Net income-$-2.82B-$-3.56B-$-4.71B$8.36B$12.2B
EPSd-$-7.25M-$-9.27M-$-12.34M$20.1M$28.3M
Operating cash flow-$-1.87B-$-3B-$-3.12B$4.98B$13.6B
Capital expenditure-$-192M-$-1.05B-$-707M-$-400M-$-284M
Free cash flow-$-2.07B-$-4.06B-$-3.83B$4.58B$13.3B
Total assets$12.3B$14.1B$18.4B$25.9B$24.7B
Total debt$1.92B$747M$1.24B$1.2B$916M
Net debt-$-679M-$-1.18B-$-1.66B-$-2.01B-$-5.93B
Total equity$8.65B$10.9B$13.9B$19.1B$14.1B
Cash and short-term investments$5.8B$7.03B$8.6B$9.9B$10.7B
Income statement
20252024202320222021
Revenue$1.94B$3.2B$6.85B$18.9B$17.7B
Cost of revenue$868M$1.46B$4.69B$5.42B$2.62B
Gross profit$1.08B$1.74B$2.16B$13.5B$15.1B
Research and development expenses$3.13B$4.54B$4.85B$3.3B$1.99B
Selling, general and administrative expenses$1.02B$1.17B$1.55B$1.13B$567M
Other expenses$0.00-$-37M$0.00-$-388M-$-735M
Operating expenses$4.15B$5.68B$6.39B$4.04B$1.82B
Cost and expenses$5.02B$7.14B$11.1B$9.46B$4.44B
Interest income$314M$425M$421M$200M$18M
Interest expense$10M$24M$38M$29M$18M
Depreciation and amortization$215M$189M$621M$348M$232M
Ebitda-$-2.55B-$-3.39B-$-3.28B$9.95B$13.5B
Operating income-$-3.07B-$-3.95B-$-4.24B$9.42B$13.3B
Total other income/expenses, net$306M$338M$297M$155M-$-11M
Income before tax-$-2.77B-$-3.61B-$-3.94B$9.58B$13.3B
Income tax expense$54M-$-46M$772M$1.21B$1.08B
Net income-$-2.82B-$-3.56B-$-4.71B$8.36B$12.2B
Weighted average shares outstanding$389M$384M$382M$394M$403M
Weighted average diluted shares outstanding$389M$384M$382M$416M$431M
Balance sheet
20252024202320222021
Cash and short-term investments$5.8B$7.03B$8.6B$9.9B$10.7B
Net receivables$284M$592M$1.08B$1.69B$3.32B
Inventory$153M$117M$202M$949M$1.44B
Total current assets$6.54B$8.1B$10.3B$13.4B$16.1B
Property, plant and equipment, net$2.85B$2.96B$2.66B$2.14B$1.38B
Goodwill and intangible assets$97M$92M$96M$0.00$0.00
Long-term investments$2.34B$2.51B$4.74B$8.36B$6.84B
Total non-current assets$5.79B$6.04B$8.1B$12.4B$8.6B
Total assets$12.3B$14.1B$18.4B$25.9B$24.7B
Accounts payable$317M$405M$520M$487M$302M
Short-term debt$0.00$37M$25M$196M$211M
Deferred revenue$99M$153M$568M$2.04B$6.25B
Total current liabilities$1.99B$2.21B$3.02B$4.92B$9.13B
Long-term debt$1.92B$710M$1.22B$1B$705M
Deferred revenue, non-current$153M$58M$83M$673M$615M
Total non-current liabilities$1.7B$1.04B$1.56B$1.81B$1.4B
Capital lease obligations$673M$747M$1.24B$1.2B$916M
Total liabilities$3.69B$3.24B$4.57B$6.74B$10.5B
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$7.22B$10B$13.6B$18.3B$9.96B
Accumulated other comprehensive income (loss)$45M-$-10M-$-123M-$-370M-$-24M
Total equity$8.65B$10.9B$13.9B$19.1B$14.1B
Total investments$5.55B$7.61B$10.4B$15.1B$10.7B
Total debt$1.92B$747M$1.24B$1.2B$916M
Net debt-$-679M-$-1.18B-$-1.66B-$-2.01B-$-5.93B
Cash flow statement
20252024202320222021
Net income-$-2.82B-$-3.56B-$-4.71B$8.36B$12.2B
Depreciation and amortization$215M$189M$621M$348M$232M
Stock-based compensation$483M$429M$305M$226M$142M
Change in working capital$254M-$-78M-$-139M-$-3.46B$1.31B
Accounts receivable$156M$534M$493M$1.79B-$-1.78B
Inventory-$-34M$83M$747M$492M-$-1.39B
Accounts payable-$-92M-$-69M$13M$240M$204M
Net cash provided by operating activities-$-1.87B-$-3B-$-3.12B$4.98B$13.6B
Investments in property, plant and equipment-$-192M-$-1.05B-$-707M-$-400M-$-284M
Acquisitions, net$0.00$0.00-$-85M$0.00$0.00
Net cash used for investing activities$1.95B$1.95B$4.21B-$-5.18B-$-8.52B
Common stock issued$35M$66M$46M$65M$124M
Common stock repurchased$0.00$0.00-$-1.15B-$-3.33B-$-857M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$593M$56M-$-1.38B-$-3.45B-$-873M
Net change in cash$668M-$-999M-$-289M-$-3.64B$4.22B
Cash at end of period$2.6B$1.93B$2.93B$3.22B$6.86B
Operating cash flow-$-1.87B-$-3B-$-3.12B$4.98B$13.6B
Capital expenditure-$-192M-$-1.05B-$-707M-$-400M-$-284M
Free cash flow-$-2.07B-$-4.06B-$-3.83B$4.58B$13.3B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Moderna, Inc.

        Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

        CEO
        Stéphane Bancel
        Employees
        4.7K
        Beta
        0.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Moderna, Inc. (MRNA)?

        Moderna, Inc. (MRNA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MRNA undervalued?

        MRNA trades at a price of $195.00 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.